{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T08:17:16Z","timestamp":1766391436881,"version":"3.48.0"},"reference-count":49,"publisher":"BMJ","issue":"7299","license":[{"start":{"date-parts":[[2001,6,9]],"date-time":"2001-06-09T00:00:00Z","timestamp":992044800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"published-print":{"date-parts":[[2001,6,9]]},"DOI":"10.1136\/bmj.322.7299.1406","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T06:43:06Z","timestamp":1027752186000},"page":"1406-1409","source":"Crossref","is-referenced-by-count":33,"title":["Obesity"],"prefix":"10.1136","volume":"322","author":[{"given":"David","family":"Arterburn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Polly","family":"Hitchcock No\u00ebl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2001,6,9]]},"reference":[{"key":"2025122109365796000_322.7299.1406.1","unstructured":"National Institutes of Health . Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the Evidence Report. Bethesda, MD: US Department of Health and Human Services, 1998."},{"key":"2025122109365796000_322.7299.1406.2","unstructured":"University of York, NHS Centre for Reviews and Dissemination . A systematic review of the interventions for the prevention and treatment of obesity, and the maintenance of weight loss. York: NHS Centre for Reviews and Dissemination, 1997."},{"key":"2025122109365796000_322.7299.1406.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.16.1519"},{"key":"2025122109365796000_322.7299.1406.4","doi-asserted-by":"crossref","unstructured":"Bray GA . Obesity: etiology. UpToDate [serial on CD Rom] 2000;8(1).","DOI":"10.1016\/S1098-3597(99)90001-7"},{"key":"2025122109365796000_322.7299.1406.5","unstructured":"Bray GA . Obesity: overview of therapy for obesity. UpToDate [serial on CD Rom] 2000;8(1)."},{"key":"2025122109365796000_322.7299.1406.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.16.1530"},{"key":"2025122109365796000_322.7299.1406.7","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18319"},{"key":"2025122109365796000_322.7299.1406.8","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.14.2185"},{"key":"2025122109365796000_322.7299.1406.9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss","volume":"7","author":"Bray","year":"1999","journal-title":"Obes Res"},{"key":"2025122109365796000_322.7299.1406.10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0800540"},{"key":"2025122109365796000_322.7299.1406.11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/clpt.1991.144","article-title":"Sibutramine in weight control: a dose-ranging, efficacy study","volume":"50","author":"Weintraub","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"2025122109365796000_322.7299.1406.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00411-2"},{"key":"2025122109365796000_322.7299.1406.13","first-page":"41","article-title":"Long-term weight loss with sibutramine [abstract]","volume":"19","author":"Jones","year":"1995","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2025122109365796000_322.7299.1406.14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","article-title":"Comparison of continuous and intermittent anorectic therapy in obesity","volume":"1","author":"Munro","year":"1968","journal-title":"BMJ"},{"key":"2025122109365796000_322.7299.1406.15","first-page":"124","article-title":"Controlled comparative investigation of mazindol, D-amphetamine, and placebo","volume":"3","author":"Vernace","year":"1974","journal-title":"Obesity Bariatric Med"},{"key":"2025122109365796000_322.7299.1406.16","doi-asserted-by":"publisher","DOI":"10.1185\/03007997309111712"},{"key":"2025122109365796000_322.7299.1406.17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1742-1241.1965.tb03144.x","article-title":"The long-term management of obesity in general practice","volume":"19","author":"Silverstone","year":"1965","journal-title":"Br J Clin Pract"},{"key":"2025122109365796000_322.7299.1406.18","first-page":"513","article-title":"Periodic health examination, 1999 update: 1. Detection, prevention and treatment of obesity. Canadian Task Force on Preventive Health Care","volume":"160","author":"Douketis","year":"1999","journal-title":"Can Med Assoc J"},{"key":"2025122109365796000_322.7299.1406.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03540230057036"},{"key":"2025122109365796000_322.7299.1406.20","first-page":"129","article-title":"Fluoxetine: a randomized clinical trial in the treatment of obesity","volume":"18","author":"Goldstein","year":"1994","journal-title":"Int J Obes"},{"key":"2025122109365796000_322.7299.1406.21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1464-5491.1994.tb00238.x","article-title":"Fluoxetine in the treatment of obese type II diabetic patients","volume":"11","author":"O'Kane","year":"1994","journal-title":"Diabet Med"},{"key":"2025122109365796000_322.7299.1406.22","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4603(76)90041-1"},{"key":"2025122109365796000_322.7299.1406.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92272-2"},{"key":"2025122109365796000_322.7299.1406.24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/clpt.1992.68","article-title":"Long term weight control study: the National Heart, Lung, and Blood Institute funded multimodal intervention study","volume":"51","author":"Weintraub","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"2025122109365796000_322.7299.1406.25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/ajcn\/55.1.203s","article-title":"Clinical studies with phenylpropanolamine: a metaanalysis","volume":"55","author":"Greenway","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"2025122109365796000_322.7299.1406.26","unstructured":"Gaasch WH Aurigemma GP . Valvular heart disease induced by anorectic drugs. UpToDate [serial on CD Rom] 2000;8(3)."},{"key":"2025122109365796000_322.7299.1406.27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1253\/jcj.64.218","article-title":"Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol: a case report","volume":"64","author":"Hagiwara","year":"2000","journal-title":"Jpn Circ"},{"key":"2025122109365796000_322.7299.1406.28","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.74.6.660"},{"key":"2025122109365796000_322.7299.1406.29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00004850-199300810-00012","article-title":"Psychosis following readministration of diethylproprion: a possible role for kindling?","volume":"8","author":"Little","year":"1993","journal-title":"Int Clin Psychopharmacol"},{"key":"2025122109365796000_322.7299.1406.30","first-page":"409","article-title":"Treatment of depression\u2014 newer pharmacotherapies","volume":"34","author":"Mulrow","year":"1998","journal-title":"Psychopharmacol Bull"},{"key":"2025122109365796000_322.7299.1406.31","first-page":"48","article-title":"Scientific and legal issues in fenfluramine\/dexfenfluramine litigation","volume":"96","author":"Poston","year":"2000","journal-title":"J Texas Med"},{"key":"2025122109365796000_322.7299.1406.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901"},{"key":"2025122109365796000_322.7299.1406.33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.ijo.0800795","article-title":"Pharmacological treatment of obesity: present status","volume":"23","author":"Scheen","year":"1999","journal-title":"Intl J Obes Relat Metab Disord"},{"key":"2025122109365796000_322.7299.1406.34","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jama.283.13.1703","article-title":"Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine and phentermine\/fenfluramine","volume":"283","author":"Gardin","year":"2000","journal-title":"JAMA"},{"key":"2025122109365796000_322.7299.1406.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809103391103"},{"key":"2025122109365796000_322.7299.1406.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608293350901"},{"key":"2025122109365796000_322.7299.1406.37","unstructured":"Horwitz RI Brass LM Kernan WN Viscoli CM . Phenylpropanolamine and risk of hemorrhagic stroke: final report of the hemorrhagic stroke project. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3647b1_tab19.doc (accessed 2 Mar 2001)."},{"key":"2025122109365796000_322.7299.1406.38","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research . Phenylpropanolamine (PPA) information page. http:\/\/www.fda.gov\/cder\/drug\/infopage\/ppa\/ (accessed 2 Mar 2001)."},{"key":"2025122109365796000_322.7299.1406.39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.7326\/0003-4819-134-4-200102200-00011","article-title":"Use of prescription weight loss pills among U.S. Adults in 1996-1998","volume":"134","author":"Khan","year":"2001","journal-title":"Ann Int Med"},{"key":"2025122109365796000_322.7299.1406.40","first-page":"2331","article-title":"Orlistat: no hurry","volume":"45","year":"1999","journal-title":"Can Fam Physician"},{"key":"2025122109365796000_322.7299.1406.41","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.9.2.160"},{"key":"2025122109365796000_322.7299.1406.42","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2000.8"},{"key":"2025122109365796000_322.7299.1406.43","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2000.00720.x"},{"key":"2025122109365796000_322.7299.1406.44","unstructured":"European Agency for the Evaluation of Medicinal Products . Committee for proprietary medicinal products. European public assessment report (EPAR)\u2014Xenical. London: European Agency for the Evaluation of Medicinal Products, 1998."},{"key":"2025122109365796000_322.7299.1406.45","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.8.1288"},{"key":"2025122109365796000_322.7299.1406.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11509-4"},{"key":"2025122109365796000_322.7299.1406.47","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.3.235"},{"key":"2025122109365796000_322.7299.1406.48","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801128"},{"key":"2025122109365796000_322.7299.1406.49","first-page":"712","article-title":"Caution when using oral contraceptive pills with Orlistat [letter]","volume":"2","author":"Peleg","year":"2000","journal-title":"Isr Med Assoc J"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.322.7299.1406","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.322.7299.1406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T17:37:07Z","timestamp":1766338627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.322.7299.1406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6,9]]},"references-count":49,"journal-issue":{"issue":"7299","published-online":{"date-parts":[[2001,6,9]]},"published-print":{"date-parts":[[2001,6,9]]}},"alternative-id":["10.1136\/bmj.322.7299.1406"],"URL":"https:\/\/doi.org\/10.1136\/bmj.322.7299.1406","relation":{},"ISSN":["0959-8138","1468-5833"],"issn-type":[{"type":"print","value":"0959-8138"},{"type":"electronic","value":"1468-5833"}],"subject":[],"published":{"date-parts":[[2001,6,9]]}}}